Our previous research indicated that TOPK activates the AKT/mTOR signal pathway and ERK signaling pathways in different esophageal cancers, suggesting potential opportunities for combination therapies with TOPK inhibitors [288, 289]. The gene discussed is PBK; the disease is esophageal cancer.